Skip to content

Treatment of Indigestion with Unani medicine Jawarish-e-Muqawwi-e-Meda

Clinical Validation of Unani Pharmacopoeial Formulation Jawarish-e-Muqawwi-e- Meda in Duf-al-Mida (Functional Dyspepsia) - NIL

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074714
Enrollment
110
Registered
2024-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K30- Functional dyspepsia

Interventions

Intervention1: Jawarish-e- Muqawwi-e- Meda: 5 gm (semisolid) orally to be taken twice daily with water after meals for 4 weeks Control Intervention1: NIL: NIL

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any sex in age group between 18-65 years. 2. Symptoms onset should start at least 6 months before diagnosis based on one or more of the following symptoms Rome IV criteria (Unpleasant postprandial fullness, early satiety, epigastric pain, and epigastric burning sensation) 3. Who meets Rome IV criteria for functional dyspepsia 4. In addition to the above, patients having any / all of the following epigastric bloating excessive belching, nausea

Exclusion criteria

Exclusion criteria: 1. Patients below 18 year and above 65 year of age 2. Patients with systemic illness e.g. Diabetes/Hypertension/Tuberculosis/Anemia. 3. Known case of Gastric peptic ulcer with H. pylori Infection or reflux esophagitis within the past 6 months were excluded 4. Gastro intestinal bleeding e.g. Hematemesis or Melena. 5. Known case of gastrointestinal surgery. 6. Known cases of Intra-abdominal malignancy (e.g. stomach/Pancreas/Liver or Gastricleiomyoma /Leiomyosarcoma/ Malignant Lymphoma)

Design outcomes

Primary

MeasureTime frame
Therapeutic efficacy of the study drug will be assessed on the basis of Response recorded using 05 score Likert dyspepsia incidence scale.Timepoint: At every 14th day of treatment for 4 weeks

Secondary

MeasureTime frame
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and after 4 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ghazala.javed@gov.in9811810454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026